CLYM116

Search documents
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
Globenewswire· 2025-08-25 18:41
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: N ...
Climb Bio to Present at Upcoming September 2025 Investor Conferences
GlobeNewswire News Room· 2025-08-25 11:00
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: Ne ...
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
Globenewswire· 2025-06-18 11:00
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated ...
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globenewswire· 2025-05-19 20:34
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company’s 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was grante ...